Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna and BioNTech Topped the Market Today

By Eric Volkman – Sep 16, 2021 at 5:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The two companies' respective coronavirus vaccines both receive a new regulatory nod.

What happened

Shares of coronavirus stocks Moderna (MRNA 0.48%) and BioNTech (BNTX 0.16%) rose on Thursday by 1.4% and 4.9%, respectively, in contrast to the stock market's dip on the day. This followed news that the two companies had their coronavirus vaccines fully approved by a national regulator.

So what

That authority is Health Canada. On Thursday morning, it switched on the green light for both Moderna's mRNA-1273 (brand-named SpikeVax) and Comirnaty from BioNTech and its development partner Pfizer (PFE -0.33%). Similar to Comirnaty's recent regulatory path in the U.S., the two shots had only been temporarily authorized for use in Canada and lacked full approval.

Person about to receive a vaccine shot from a healthcare professional.

Image source: Getty Images.

The regulator's nod covers patients 12 years of age and older. Recently, Health Canada expanded its authorization to cover people ages 12 to 17 for both shots.

It's interesting that BioNTech's stock moved notably higher than that of Moderna. After all, Health Canada's approval is SpikeVax's first by a major regulator (although it has been granted emergency use authorization in over 50 jurisdictions, including the U.S.).

The Pfizer/BioNTech and Moderna jabs are not the first ones to be authorized in the country to combat the resurgent coronavirus.

In February, Health Canada approved Vaxzevria, co-developed by pharmaceutical sector giant AstraZeneca and the U.K.'s Oxford University. However, the government soon suspended its use for individuals under 55 due to apparent links to rare blood clots and concerns about supply issues. Finally, the one-shot vaccine from Johnson & Johnson's Janssen unit received its approval in March.

In contrast to the newcomers, though, the AstraZeneca and the Johnson & Johnson jabs have only been approved for individuals 18 and older.

Now what

While the change in status of a previously authorized vaccine isn't much of a game-changer, Health Canada's move could help bring out reluctant people who cited the lack of full approval as reasons for not getting a shot. Additionally, it strengthens the Pfizer/BioNTech and Moderna vaccines as go-to solutions for fighting the still-menacing international health threat.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson and Moderna Inc. The Motley Fool has a disclosure policy.

Stocks Mentioned

Moderna Stock Quote
Moderna
MRNA
$182.35 (0.48%) $0.87
Pfizer Stock Quote
Pfizer
PFE
$50.91 (-0.33%) $0.17
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$178.88 (0.08%) $0.14
AstraZeneca Plc Stock Quote
AstraZeneca Plc
AZN
$68.47 (0.19%) $0.13
BioNTech Se Stock Quote
BioNTech Se
BNTX
$169.74 (0.16%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.